Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944220 | 0.78 | MEN1 (0.53) | POLBMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL2157251 | 0.77 | TSHR (0.71) | POLBMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL3934517 | 0.77 | GAA (0.68) | POLBMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL3934524 | 0.77 | GAA (0.68) | POLBMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL14019092 | 0.77 | TP53 (0.42) | POLBMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL2448205 | 0.76 | SMN1; SMN2 (0.53) | POLBMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL19615056 | 0.76 | SMN1; SMN2 (0.53) | POLBMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL2156809 | 0.76 | KDM4E (0.55) | POLBMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL8299383 | 0.75 | MMP13 (0.70) | TP53 | |
| SCHEMBL3937241 | 0.75 | ADRB1 (0.56) | LMNAMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| EP-1644340-A1 | N-{'4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL]ALKYL}-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | POLB 1157/4885MEN1 786/4885KMT2A 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.